Theophylline Anhydrous: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Theophylline Anhydrous. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Sinus tachycardia | 100% |
| Hyperglycemia | 98% |
| Vomiting | 93% |
| Hypokalemia | 85% |
| Nervousness | 64% |
| Hemodynamic instability | 40% |
| Tremors | 38% |
| Acid/base disturbance | 34% |
| Abdominal pain | 21% |
| Other supraventricular tachycardias | 21% |
| Ventricular premature beats | 21% |
| Hypotension/shock | 21% |
| Death | 21% |
| Diarrhea | 14% |
| Seizures | 14% |
| Atrial fibrillation or flutter | 12% |
| Disorientation | 11% |
| Rhabdomyolysis | 7% |
| Asymptomatic | 6% |
| Hematemesis | 2% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Source: FDA labeling via NIH DailyMed (set 098db8bb…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.